JW Therapeutics

About JW Therapeutics

JW Therapeutics (HKEx: 2126) is an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, the company has built an integrated platform and pipeline spanning hematologic malignancies, solid tumors and autoimmune diseases. As a commercial-stage CAR-T company, JW Therapeutics is committed to bringing breakthrough, high-quality cell therapies such as Carteyva® to patients in China and beyond, improving survival and quality of life and advancing the healthy, standardized development of the cell therapy industry.